Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Johnson & Johnson, EBITDA calculation
US$ in millions
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Johnson & Johnson EBITDA decreased from 2022 to 2023 but then slightly increased from 2023 to 2024. |
Enterprise Value to EBITDA Ratio, Current
Johnson & Johnson, current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 411,391) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 24,781) |
| Valuation Ratio | |
| EV/EBITDA | 16.60 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| AbbVie Inc. | 28.94 |
| Amgen Inc. | 16.13 |
| Bristol-Myers Squibb Co. | 51.33 |
| Danaher Corp. | 22.05 |
| Eli Lilly & Co. | 53.42 |
| Gilead Sciences Inc. | 35.22 |
| Merck & Co. Inc. | 9.73 |
| Pfizer Inc. | 10.36 |
| Regeneron Pharmaceuticals Inc. | 11.85 |
| Thermo Fisher Scientific Inc. | 18.57 |
| Vertex Pharmaceuticals Inc. | 243.67 |
| EV/EBITDA, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 22.07 |
| EV/EBITDA, Industry | |
| Health Care | 20.19 |
Based on: 10-K (reporting date: 2024-12-29).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Johnson & Johnson, historical EV/EBITDA calculation, comparison to benchmarks
| Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 390,710) | 383,498) | 428,242) | 439,101) | 435,585) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 24,781) | 23,320) | 28,971) | 30,349) | 23,929) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 15.77 | 16.45 | 14.78 | 14.47 | 18.20 | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| AbbVie Inc. | 26.97 | 20.79 | 13.31 | 13.44 | 21.34 | |
| Amgen Inc. | 15.31 | 14.13 | 12.97 | 13.22 | 12.24 | |
| Bristol-Myers Squibb Co. | 48.23 | 6.51 | 9.46 | 8.65 | 34.35 | |
| Danaher Corp. | 22.34 | 26.41 | 18.42 | 21.05 | 26.68 | |
| Eli Lilly & Co. | 55.98 | 85.33 | 37.74 | 29.85 | 23.67 | |
| Gilead Sciences Inc. | 35.86 | 10.41 | 13.89 | 8.57 | 24.90 | |
| Merck & Co. Inc. | 9.90 | 51.30 | 13.91 | 12.18 | 16.05 | |
| Pfizer Inc. | 10.60 | 22.50 | 6.12 | 8.64 | 15.78 | |
| Regeneron Pharmaceuticals Inc. | 13.55 | 20.16 | 15.27 | 6.68 | 12.70 | |
| Thermo Fisher Scientific Inc. | 19.89 | 21.83 | 20.25 | 20.21 | 18.72 | |
| Vertex Pharmaceuticals Inc. | 231.93 | 21.57 | 14.91 | 18.92 | 14.81 | |
| EV/EBITDA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 22.07 | 22.59 | 13.58 | 13.16 | 18.90 | |
| EV/EBITDA, Industry | ||||||
| Health Care | 19.95 | 18.98 | 13.71 | 13.87 | 16.50 | |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
3 2024 Calculation
EV/EBITDA = EV ÷ EBITDA
= 390,710 ÷ 24,781 = 15.77
4 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Johnson & Johnson EV/EBITDA ratio increased from 2022 to 2023 but then slightly decreased from 2023 to 2024. |